ArticleBMC pregnancy and childbirth2026
Impact of different sufentanil concentrations in epidural labor analgesia on maternal and neonatal outcomes: a propensity score-matched cohort study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe optimal sufentanil concentration for patient-controlled epidural analgesia (PCEA) during labor remains uncertain. This study evaluated the association between sufentanil concentration strategies and maternal-neonatal outcomes.
methodsThis single-center retrospective cohort study included parturients receiving sufentanil-containing epidural labor analgesia. Patients were stratified by fixed sufentanil concentration in the PCEA formulation. The observed concentration range was 0.25-0.50 µg/mL, and the median value of 0.30 µg/mL defined the Low-concentration group (≤ 0.30 µg/mL) and High-concentration group (> 0.30 µg/mL). One-to-one propensity score matching (PSM) was used to balance baseline confounders. The single primary endpoint was a composite safety outcome defined as any analgesia-related adverse event, including nausea and vomiting, pruritus, or lower limb motor blockade. Secondary outcomes included Visual Analog Scale (VAS) pain scores, breakthrough pain, PCEA bolus use, maternal satisfaction, labor outcomes, and neonatal metrics.
resultsA total of 314 matched patients were analyzed. Both groups showed similar end-stage VAS scores and maternal satisfaction (P = 0.412), although the Low-concentration group required more PCEA boluses (median: 5 vs. 3; P = 0.004). The High-concentration group had more opioid-related maternal adverse events, including pruritus (31.8% vs. 14.6%; P < 0.001), nausea and vomiting, and minor motor blockade. High-concentration sufentanil was associated with higher odds of prolonged second stage of labor (adjusted odds ratio = 1.85; 95% confidence interval: 1.08-3.16).
conclusionsLow-concentration sufentanil was associated with broadly comparable analgesic effectiveness and fewer opioid-related maternal adverse events. The second-stage difference was statistically significant but clinically modest and did not translate into significant differences in delivery mode, postpartum hemorrhage, or neonatal outcomes. These findings should be interpreted as hypothesis-generating real-world evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.